新华制药(000756.SZ)：富马酸伏诺拉生化学原料药上市申请获批准

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the marketing application of fumaric acid volnorasone, which is primarily used for treating gastroesophageal reflux disease [1] Group 1 - The approval signifies a regulatory milestone for the company, potentially enhancing its product portfolio in the pharmaceutical market [1] - Fumaric acid volnorasone is specifically indicated for gastroesophageal reflux disease, indicating a targeted therapeutic application [1]